Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desmopressin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A known ✓ | P37288 | 5/20 | 1.00 |
| ▸ | AVPR2 known ✓ | P30518 | 3/20 | 1.00 |
| ▸ | AVPR1B known ✓ | P47901 | 3/20 | 1.00 |
| ▸ | OXTR | P30559 | 8/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desmopressin SCHEMBL29387302 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL29454824 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL29935850 | 0.98 | OXTR (0.97) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL1172203 | 0.98 | OXTR (0.97) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL1171610 | 0.98 | OXTR (0.96) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Vasopressin SCHEMBL18937546 | 0.94 | AVPR1A (1.00) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Vasopressin SCHEMBL29688276 | 0.94 | AVPR1A (1.00) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Vasopressin SCHEMBL19712236 | 0.94 | AVPR1A (1.00) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Vasopressin SCHEMBL17874853 | 0.94 | AVPR1A (1.00) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| SCHEMBL31061295 | 0.93 | AVPR2 (0.87) | OXTRAVPR1AAVPR2AVPR1BPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 25420 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746850-A1 | EXTENDED RELEASE DRUG-LOADED MICROPARTICLES | Ferring BV (NL) | 2026-05-27 | — | — | EP | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-4722725-A2 | COMPOSITIONS AND METHODS FOR EVALUATION OF ANTIPLATELET DRUG SENSITIVITY | Beth Israel Deaconess Medical Center, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-12576125-B2 | Desmopressin oral compositions | TULEX PHARMACEUTICALS INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4687859-A2 | DESMOPRESSIN ORAL COMPOSITIONS | TULEX PHARMACEUTICALS, INC. (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2026-01-29 | — | — | US | claimed |
| US-20260028460-A1 | Erodible Film and Method of Making | VIPA PHARMA INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-0122036-B1 | POWDERY PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION | TEIJIN LIMITED (JP) | 1989-02-08 | — | — | EP | claimed |
| EP-0300036-A1 | VASOPRESSIN-BASED PHARMACEUTICAL COMPOSITIONS | CORINT LIMITED (CH) | 1989-01-25 | — | — | EP | claimed |
| EP-0278474-A1 | Electrolytic transdermal delivery of polypeptides | Drug Delivery Systems Inc. (US) | 1988-08-17 | — | — | EP | claimed |
| US-4764378-A | MATRICES OF HIGH AND LOW MOLECULAR WEIGHT POLYOXYETHYLENE GLYCOLS | ZETACHRON, INC. (US) | 1988-08-16 | — | — | US | claimed |
| WO-1988005661-A1 | VASOPRESSIN-BASED PHARMACEUTICAL COMPOSITIONS | BIOMED RESEARCH CONSULTANTS, LIMITED (CH) | 1988-08-11 | — | — | WO | claimed |
| EP-0252732-A2 | Transdermal drug delivery device | ELAN TRANSDERMAL LIMITED (IE) | 1988-01-13 | — | — | EP | claimed |
| EP-0232877-A2 | Buccal drug dosage form | ZETACHRON, INC. (US) | 1987-08-19 | — | — | EP | claimed |
| US-4613500-A | POLYPERTIDE AND BASE | TEIJIN LIMITED (JP) | 1986-09-23 | — | — | US | claimed |
| EP-0193372-A2 | Intranasally applicable powdery pharmaceutical composition | TEIJIN LIMITED (JP) | 1986-09-03 | — | — | EP | claimed |
| EP-0122036-A1 | Powdery pharmaceutical composition for nasal administration | TEIJIN LIMITED (JP) | 1984-10-17 | — | — | EP | claimed |